Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Attalla, Kyrollis; Weng, Stanley; Voss, Martin H.; Hakimi, A. Ari

doi:10.1016/j.ucl.2020.04.002

Cited by 40 publications

(33 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite their efficacy, not all mRCC patients achieve a long-term benefit from ICIs, either given as single agent or in combination (20–30%). 5 , 6 It should be noted that mRCC is often associated with a highly-variable clinical course, spanning from indolent to rapidly-progressing disease, 7 as a reflection of its well-known heterogeneity. 9 …”

Section: Introductionmentioning

confidence: 99%

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

et al. 2021

View full text Add to dashboard Cite

Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated the prognostic role of peripheral-blood inflammatory indices and clinical factors to develop a novel prognostic score in mRCC patients receiving at least second-line nivolumab. The complete blood count before the first cycle of therapy was assessed by calculating neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), and systemic inflammation response index (SIRI). Clinical factors included pre-treatment International Metastatic RCC Database Consortium (IMDC) score, line of therapy, and metastatic sites. Results: From October 2015 to November 2019, 571 mRCC patients received nivolumab as second- and further-line treatment in 69% and 31% of cases. In univariable and multivariable analyses all inflammatory indices, IMDC score, and bone metastases significantly correlated with overall survival (OS). The multivariable model with NLR, IMDC score, and bone metastases had the highest c-index (0.697) and was chosen for the developing of the score (Schneeweiss scoring system). After internal validation (bootstrap re-sampling), the final index (Meet-URO score) composed by NLR, IMDC score, and bone metastases had a c-index of 0.691. It identified five categories with distinctive OSs: group 1 (median OS – mOS = not reached), group 2 (mOS = 43.9 months), group 3 (mOS = 22.4 months), group 4 (mOS = 10.3 months), and group 5 (mOS = 3.2 months). Moreover, the Meet-URO score allowed for a fine risk-stratification across all three IMDC groups. Conclusion: The Meet-URO score allowed for the accurate stratification of pretreated mRCC patients receiving nivolumab and is easily applicable for clinical practice at no additional cost. Future steps include its external validation, the assessment of its predictivity, and its application to first-line combinations.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Its incidence has been increasing at a rate of about 2% annually, with more than 200,000 new cases worldwide per year ( Siegel et al, 2019 ). Despite advances in surgical techniques, the overall 5-year survival rate of patients in early-stage RCC is approximately 93%, whereas that of patients with metastatic RCC is approximately12% ( Siegel et al, 2017 ; Attalla et al, 2020 ). Therefore, it is imperative to develop novel targets against RCC.…”

Section: Introductionmentioning

confidence: 99%

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma

Tian

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Autophagy is a process that degrades and recycles superfluous organelles or damaged cellular contents. It has been found to have dual functions in renal cell carcinoma (RCC). Many autophagy-related proteins are regarded as prognostic markers of RCC. Researchers have attempted to explore synthetic and phytochemical drugs for RCC therapy that target autophagy. In this review, we highlight the importance of autophagy in RCC and potential treatments related to autophagy.

show abstract

“…The inclusion criteria for ccRCC samples in lncRNA signature construction and validation included: (1) samples with complete lncRNA expression levels, and (2) samples with total survival time over 30 days. Subsequently, the eligible ccRCC samples were randomly divided into the training and testing cohorts on the ratio of 7:3 by caret R package.…”

Section: Methodsmentioning

confidence: 99%

“…With 208,500 new cases diagnosed worldwide each year, the renal tumor is one type of common malignancies in urinary tumors. ccRCC is the most common type of renal tumor, accounting for approximately 80% of the types of renal tumor 1 . The invasive features and unfavorable prognosis contribute to high morbidity and mortality of ccRCC 2 .…”

Section: Introductionmentioning

confidence: 99%

Identification of a hypoxia-associated long non-coding RNA signature and nomogram as a prognostic target for clear cell renal cell carcinoma

Chen¹,

Pan²,

Jin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To develop a hypoxia-associated long non-coding (lncRNA) signature for risk stratification in clear cell renal cell carcinoma (ccRCC). Methods The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA KIRC) dataset was downloaded and analyzed. Results Four prognostic hypoxia-associated lncRNAs were used for signature construction. The four lncRNAs were downregulated in high grade, advanced stage, and high-risk ccRCC. ccRCC patients in the high-risk group had a worse prognosis than those in the low-risk group. And the risk score was significantly higher in high grade and advanced stage. The signature had an independent and long-standing prognosis prediction ability up to 10-year follow-up. Notably, the risk score was significantly positively correlated with the infiltration abundances of six immune cells from the Tumor IMmune Estimation Resource (TIMER). The gene set enrichment analysis (GSEA) also suggested that the signature was involved in the metabolism and tumorigenesis, which were closely related to the hypoxic tumor microenvironment. Ultimately, a nomogram was built to predict the individual long-term survival possibility. Conclusions We have developed a new hypoxia-associated lncRNA signature, representing a promising tool for risk stratification tool in ccRCC. It might serve as a prognostic index to facilitate personalized counseling for treatment.

show abstract

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Cited by 40 publications

References 62 publications

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma

Identification of a hypoxia-associated long non-coding RNA signature and nomogram as a prognostic target for clear cell renal cell carcinoma

Contact Info

Product

Resources

About